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Abstract
Salivary gland tumors comprise a group of 24 tumor subtypes with a wide range of clinical
behaviors and propensities for metastasis. Several prognostic factors have been identified that help
predict the development of systemic metastases, most commonly to the lung, liver, or bone.
Metastases to the brain are rare. To better understand the behavior of salivary gland tumors that
metastasise to the brain, we performed a retrospective cohort analysis on a series of patients to
highlight features of their medical and surgical management. From 2007 to 2011, a database of
4117 elective craniotomies were queried at a single institution to identify patients surgically
treated for salivary gland metastases to the brain. Three patients were identified. Histologic
subtypes included salivary duct carcinoma, poorly differentiated carcinoma, and papillary
mucinous adenocarcinoma. They had all undergone previous treatment for their primary
malignancy. The mean time to intracranial metastasis was 48 months from initial diagnosis (range,
14–91 months). Treatment for intracranial metastases included surgical resection, whole brain
radiation, stereotactic radiosurgery, and chemotherapy. Intracranial metastases from salivary gland
tumors are rare, present years after diagnosis of the primary tumor, and are treatable with
multimodality therapy.
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1. Introduction
Salivary gland malignancies comprise a heterogeneous group of tumors with different
propensities for metastasis. Salivary gland malignancies have an estimated incidence of 0.5–
2.5 per 100,000 people.1–3 In the US, incidence of salivary gland cancer has increased
significantly towards the end of the 1990s, from 6.3% in 1974–1976 to 8.1% of all head and
neck cancers in 1998–1999.4 Most arise from the parotid glands (70–80%), with the
remainder arising from submandibular gland (10%) or sublingual and minor salivary glands
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(5%).3 Survival in adults is approximately 83% at 1 year, 69% at 3 years and 65% at 5 years.
Prognostic factors include sex and age. Women typically have higher survival rates than
men (72% versus 58%), and the 5 year survival is higher among patients aged 15–45 versus
those older than 75 years (87% and 59%, respectively).5
Since the majority of patients have long survival times following initial diagnosis, the
development of metastatic disease is relatively common. For example, high-grade salivary
ductal carcinoma eventually metastasizes in 46% of patients, often with indolent courses.6
The most common sites for metastases are lung (80%), bone (15%), and liver and other sites
(5%). Metastases to the brain are very rare with only limited data available in the
literature.7–15 Surgery and radiation are traditionally the mainstays for therapy both for
primary as well as metastatic lesions. We report a series of salivary gland malignancy with
metastases to the brain to highlight this rare clinical entity and review the medical and
surgical management.
2. Methods
Following institutional board approval, a retrospective analysis was performed during the
period of 2007–2011 at a single, quaternary-level care neurosurgical center. Four thousand,
one hundred and seventeen craniotomies were identified during the period that were
subsequently queried for histopathology consistent with salivary gland metastases. Each
case was reviewed by a neuropathologist (MS) and diagnosis was confirmed. The electronic
medical record was queried for treatment history including clinic notes, hospital notes,
operative notes, radiation treatment dosimetry plans, and neuroimaging.
3. Results
3.1 Patient 1
A 60-year-old woman presented with a lump under the angle of her right mandible. She
underwent resection and neck dissection and was found to have a primary 1.5 cm salivary
duct carcinoma of the right submandibular gland with vascular and perineural invasion.
Metastases were found in three of 19 regional lymph nodes. Immunohistochemistry was
positive for amplification of HER2/Neu. Postoperatively, she completed a concurrent course
of cisplatin and radiotherapy. Follow-up surveillance CT scans performed 6 months later
demonstrated multiple pulmonary nodules consistent with metastatic disease. Two years
following the original diagnosis, MRI of the spine demonstrated vertebral body metastases
from T8 to T12 causing lower thoracic pain that was palliated with radiotherapy (35 Gy) and
concurrent chemotherapy (taxol and trastuzumab).
She continued on trastuzumab monotherapy for 1 year without symptoms until she presented
with unsteady gait. Brain MRI revealed a contrast enhancing 1.5 cm right cerebellar mass
(Fig. 1a–c), as well as right parietal and left frontal masses. She underwent a suboccipital
craniotomy to resect her cerebellar mass, followed by 35 Gy whole brain radiation
administered in 14 fractions, followed by a boost of 18 Gy with stereotactic proton
radiosurgery to the right parietal lesion. Four years following the initial diagnosis, she had a
generalized seizure that began with left arm and leg twitching. A CT scan of the brain
demonstrated hemorrhage into the right parietal lesion (she was being treated with low
molecular weight heparin at the time for an incidentally discovered pulmonary embolism).
Anticoagulation was discontinued and an inferior vena cava filter was placed. She
underwent right parietal craniotomy for tumor resection. Histopathological review
confirmed an adenocarcinoma with extensive necrosis consistent with metastasis from her
salivary gland tumor (Fig. 1d, e). Her postoperative course was complicated by intermittent
seizure activity despite high-dose levetireacetam.
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Unfortunately, widespread brain disease progression was found on routine surveillance
imaging 3 months after the second craniotomy. After discussion with the patient and her
family about her goals of care, she was transitioned to hospice care.
3.2 Patient 2
A 52-year-old woman presented with neck swelling and progressive trismus over 3 months.
MRI of the head and neck revealed a deep parotid mass measuring 1.4 cm, with involvement
of the mandible and pterygoids at the skull base. Positron emission tomography
demonstrated intense uptake of the parotid mass and a level II neck lymph node. She
underwent open biopsy for definitive diagnosis, which showed a poorly differentiated
carcinoma that was positive for keratin staining but negative for S100. Due to the
unresectability of the primary lesion, she underwent concurrent chemoradiation with
carboplatin and taxol. The left neck field received 60 Gy over 3 months with a 10 Gy boost
to the primary lesion and involved lymph node. One year later, routine surveillance MRI of
the neck revealed an asymptomatic ring-enhancing left temporal lobe lesion (Fig. 2a–c). She
underwent left temporal craniotomy for surgical resection of the enhancing mass. Pathologic
analysis of the temporal lobe specimen demonstrated poorly differentiated carcinoma with
similar morphological and immunohistochemical features to the parotid primary tumor (Fig.
2d, e). She was subsequently treated with stereotactic radiosurgery of 15 Gy to the residual
disease in the left temporal resection cavity. Surveillance imaging of the parotid and
temporal lesions have shown a good response thus far. The most recent brain MRI a year
following the craniotomy demonstrated a slight increase in size of the remaining enhancing
lesion in the left temporal lobe.
3.3 Patient 3
A 48-year-old man presented with a several year history of gradually enlarging mass in the
posterior mouth. A biopsy demonstrated papillary mucinous adenocarcinoma arising from a
minor salivary gland. Staging CT scans and MRI demonstrated the primary mass with
extension to the soft palate, anterior pillar, and retromolar trigone but no lymphadenopathy.
He was treated by surgical resection and postoperative radiotherapy.
Surveillance imaging 1 year later identified bilateral pulmonary metastases that were
managed by surgical resection and radiofrequency ablation. Pathology demonstrated a
mucinous adenocarcinoma, which was progesterone receptor positive, estrogen receptor
negative tumor without over-expression of HER2/Neu. Another year later, his pulmonary
lesions had progressed and capacitabine chemotherapy was started and led to disease
stability. However, 3 years following the initial diagnosis, he was found to have distant
metastases to the calf and the chest wall. The calf lesion was resected with close margins,
but later recurred and was treated with radiotherapy. Gemcitobine chemotherapy had little
perceived effect and he was enrolled in a clinical trial for small molecule chemotherapy
targeting phosphatidyl inositol kinase mutated tumors.
Unfortunately, 4 years following initial diagnoisis, he developed gait instability and
dizziness. A brain MRI revealed four intracranial lesions, highlighted by a dominant 3.2 cm
left cerebellar mass (Fig. 3a–d). He underwent craniotomy for resection of the cerebellar
mass, and histopathology was consistent with metastasis of the salivary gland primary tumor
with extensive mucin production (Fig. 3e, f). He then underwent 14 fractions of whole brain
radiation totaling 35 Gy. He is currently doing well at his 6 month follow-up with
intermittent headaches. He is being followed with surveillance imaging.
Venteicher et al. Page 3
J Clin Neurosci. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4. Discussion
Salivary gland tumors comprise 24 different histologic subtypes, as classified by the World
Health Organisation histological classification published in 2005.16 Aggressive subtypes
include anaplastic carcinoma, squamous cell carcinoma, carcinoma in pleomorphic
adenoma, high-grade mucoepidermoid tumors, salivary duct carcinoma, oncocytic
carcinoma, and large cell carcinoma.6 Prognosis and propensity for distant metastases
correlates with histology, grade, facial nerve paralysis for parotid tumors, lymphovascular or
perineural invasion, and HER2/Neu status.6 It should be noted that intracranial direct
extension of the tumor is not the same as hematogenous metastatic spread.17
This series highlights prognostic features that correlate with systemic metastasis of salivary
gland tumors and management strategy for brain metastases. In the patients described here,
each had a distinct histologic subtype which has previously been described as having
aggressive clinical behavior. In addition, histopathologic features including HER2/Neu
amplification, which is seen in 57–73% of salivary gland tumors, correlates with poorer
prognosis.18,19 Patient 1 had evidence of lymphvascular/perineural involvement and HER2/
Neu amplication on histologic analysis of the primary tumor. Patient 2 had a high-grade and
unresectable primary tumor, and as such was treated with radiation alone. Patient 3 had
regional extension of the primary tumor at the time of initial resection despite normal HER2/
Neu expression, and subsequently had a long interval between diagnosis of the primary
tumor and the development of symptomatic brain metastases. These characteristics of
aggressive salivary gland tumors should prompt close surveillance of these patients for the
development of systemic and central nervous system metastases.
Brain metastases develop as late sequelae in patients with salivary gland malignancy. Two
patients had symptomatic brain lesions, while one patient had an incidentally discovered
asymptomatic brain metastasis. Symptomatic lesions presented approximately 3 and 7 years
after the primary tumor was diagnosed (Table 1). Management of these brain metastases for
salivary gland tumors was essentially the same as the general management for brain
metastases for other tumor types (Table 1). Symptomatic lesions are resected if the tumor
location is favorable. The evidence for this is based on the time-tested evidence reported by
Patchell et al. that patients with a single metastasis who are treated by surgical resection plus
radiotherapy live longer, have fewer local recurrences, and have an improved quality of life
compared with radiation therapy alone.20
Radiotherapy, either to the tumor bed via stereotactic radiosurgery (in the case of single
brain metastasis) and/or whole brain radiation (in the case of multiple lesions), is then used
postoperatively. This highlights a current area of study: the efficacy of stereotactic
radiosurgery for the treatment of brain metastasis following surgical resection. It is well
known that whole brain radiotherapy can have detrimental neurocognitive effects, making
localized therapy such as stereotactic radiosurgery a potentially more attractive alternative.
However, in a prospective radomized trial of brain metastases treated with either whole
brain radiotherapy or whole brain radiotherapy plus stereotactic radiosurgery, control of the
brain tumor was found to be the most important factor for stabilizing neurocognitive
function. Even so, the long-term effects of whole brain radiation are certainly not
negligible.21 Directly addressing this question is a phase III trial of post-surgical stereotactic
radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease
(ClinicalTrials. gov identifier NCT01372774). Additionally, a dose escalation phase II
clinical trial is currently underway to identify the maximally safe dose of stereotactic
radiosurgery that can be administered following surgical resection of brain metastases in an
attempt to improve local control by increasing radiation dosage (ClinicalTrials. gov
identifier NCT00587964).
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The scarcity of salivary gland tumors with intracranial metastases makes clinical trials of
chemotherapy difficult. Several agents have shown benefit in non-randomized studies, with
carboplatin and paclitaxel being the most frequently used.22,23 Also, trastuzumab has been
shown to have low activity levels in HER2/Neu overexpressing salivary gland tumors in a
phase II study.24 Small molecules targeting cancers with distinct molecular profiles, such as
the case in Patient 3, are currently being evaluated (ClinicalTrials. gov identifier:
NCT01390818).
5. Conclusions
Salivary gland malignancies have a protracted course which often results in systemic
metastasis. The primary tumor is most often treated with surgical resection and
postoperative radiation to the tumor bed. Systemic metastases most often affect the lungs
and require the addition of chemotherapy. As surgical and chemoradiation therapies have led
to increased control of primary and systemic disease, the number of patients displaying brain
metastases may continue to rise as patients live longer. When brain metastases grow or are
symptomatic, then surgical resection is indicated. Postoperative radiation, either with
stereotactic radiosurgery to the tumor bed or whole brain radiation in the case of multiple
brain metastases, is used to limit recurrence. While not yet a main aspect of the treatment of
central nervous system metastasis, chemotherapy with activity towards salivary gland
tumors with central nervous system penetration will be an important addition to the future
armamentarium of adjunctive therapies. Since many salivary gland tumors grow relatively
slowly, this strategy of multimodality therapy may lead to lasting control of malignant
disease.
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Fig. 1.
Patient 1 with metastasis from salivary duct carcinoma. Post-contrast MRI of (a) axial
section showing the right cerebellar lesion, (b) axial section showing the right parietal
lesion, (c) coronal section showing both the right cerebellar and parietal lesions.
Histopathology samples showing (d) adenocarcinoma with extensive necrosis (original
magnification × 400), with (e) scattered glands present in otherwise entirely necrotic
background (original magnification × 100).
Venteicher et al. Page 7
J Clin Neurosci. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
Patient 2 with metastasis from poorly differentiated carcinoma. Post-contrast MRI of (a)
axial section showing the left temporal lesion, (b) coronal section showing the left temporal
lesion, and (c) saggital section showing the left temporal lesion. Histopathology samples
showing (d) poorly differentiated cells with large nuclei and prominent nucleoli at high-
power view (original magnification × 400), and (e) sheets of cells without gland formation
(original magnification × 100).
Venteicher et al. Page 8
J Clin Neurosci. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 3.
Patient 3 with metastasis from papillary mucinous adenocarcinoma. Post-contrast MRI of
(a) axial section showing the left cerebellar lesion, (b) axial section showing the right
parietal and cingulate lesions, (c) coronal section showing the right parietal and left
cerebellar lesions, and (d) saggital section showing the left cerebellar lesion. Histopathology
samples showing (e) adenocarcinoma with abundant mucin production (original
magnification × 400), with (f) occasional glands floating in pools of mucin (original
magnification × 100).
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